HR Execs on the Move

Motus GI

www.motusgi.com

 
Motus GI Holdings, Inc. (NASDAQ: MOTS) is a medical technology company based in the U.S., with subsidiaries in the U.S. and Israel, dedicated to improving endoscopy outcomes, lowering costs and enhancing patient experiences. The Company is focused on the development and commercialization of the Pure-Vu® System, designed to improve the colonoscopy experience and assist in the early detection and prevention of colorectal cancer and other diseases of the rectum and colon.
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million
  • www.motusgi.com
  • 1301 E. Broward Blvd. Suite 310
    Fort Lauderdale, FL USA 33301
  • Phone: 954.541.8000

Executives

Name Title Contact Details
Jeff Gnagi
 Vice President, US Sales Profile

Similar Companies

SuperSonic Imagine

SuperSonic Imagine designs, develops and markets a new generation ultrasound system, Aixplorer, with an UltraFast platform that can acquire images 200 times faster than conventional ultrasound systems. Aixplorer is the only system that can image two types of waves: ultrasound waves ensure excellent image quality and shear waves, which allow physicians to visualize and analyze the stiffness of tissue in a real-time, reliable, reproducible and non-invasive manner. This innovation, ShearWave™ Elastography, significantly improves the detection and characterization of numerous pathologies in several applications including breast, thyroid, liver and prostate.

Healthcare Management Systems

Since 1984, HMS has been the leader in hospital information systems focusing on rural, community, behavioral, rehabilitation and multi-entity healthcare organizations.

Chapman Lake Instrument Corp

Chapman Lake Instrument Corp is a Bloomington, IN-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

InstaMed

InstaMed is a Philadelphia, PA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Perspective Therapeutics

We develop game-changing therapies that make an impactful difference for cancer patients and the clinicians who treat them.